Desmocollin switching in colorectal cancer by Khan, K et al.
Short Communication
Desmocollin switching in colorectal cancer
K Khan
1, R Hardy
1, A Haq
2, O Ogunbiyi
2, D Morton
1 and M Chidgey*,1
1Division of Medical Sciences, University of Birmingham, Clinical Research Block, Queen Elizabeth Hospital, Birmingham B15 2TH, UK;
2Department of
Surgery, Royal Free Hospital, Pond Street, London NW3 2QG, UK
The desmocollins are members of the desmosomal cadherin family of cell–cell adhesion molecules. They are essential constituents of
desmosomes, intercellular junctions that play a critical role in the maintenance of tissue integrity in epithelia and cardiac muscle. In
humans, three desmocollins (Dsc1, Dsc2 and Dsc3) have been described. The desmocollins exhibit tissue-specific patterns of
expression; only Dsc2 is expressed in normal colonic epithelium. We have found switching between desmocollins in sporadic
colorectal adenocarcinoma with a reduction in Dsc2 protein (in 8/16 samples analysed by immunohistochemistry) being
accompanied by de novo expression of Dsc1 (16/16) and Dsc3 (7/16). Similar results were obtained by western blotting of a further
16 samples. No change was found in Dsc2 mRNA, but de novo expression of Dscs 1 and 3 was accompanied by increased message
levels. Loss of Dsc2 (8/19) and de novo expression of Dsc1 (11/19) and Dsc3 (6/19) was also found in colorectal adenocarcinomas on
a background of colitis. The data raise the possibility that switching of desmocollins could play an important role in the development
of colorectal cancer.
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Tumour development is in part characterised by the ability of cells
to overcome cell–cell adhesion and invade the surrounding tissue.
Two of the principal types of intercellular junctions of epithelia are
adherens junctions (AJs) and desmosomes. Adherens junctions
contain classical cadherins such as the tumour suppressor gene
product E-cadherin. Loss of E-cadherin and a concomitant
increase in another classical cadherin, N-cadherin, is a defining
feature of the epithelial to mesenchymal transition, found in
embryogenesis, organ development and neoplasia (Lee et al, 2005).
This so-called ‘cadherin switch’ has been documented in a variety
of cancers (Tomita et al, 2000; Hardy et al, 2002), and is thought to
confer on benign tumour cells the capacity to invade surrounding
tissue and ultimately to metatasise to distant sites (Lee et al, 2005).
The desmosomal cadherins (DCs), of which there are seven in
humans, three desmocollins (Dsc1–3) and four desmogleins
(Dsg1-4), are membrane-spanning adhesion molecules of desmo-
somes. Genetic ablation of Dsc1 and Dsg3 results in epidermal
blistering in transgenic mice, illustrating the importance of these
molecules for the maintenance of normal intercellular adhesion
(Koch et al, 1997; Chidgey et al, 2001). Loss of expression of DCs
has been documented in various cancers (see Chidgey, 2002;
Biedermann et al, 2005; Oshiro et al, 2005) and overexpression of
DCs in nonadhesive cultured fibroblasts generates adhesion and
inhibits invasion (Tselepis et al, 1998), supporting the idea that
DCs have a tumour suppressor role. In this study, we have
examined the expression of the desmocollins in two groups of
colorectal tumours: sporadic adenocarcinomas and colorectal
adenocarcinomas arising on a background of colitis. We show
for the first time that switching between nonclassical cadherins
occur in neoplasia.
MATERIALS AND METHODS
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of sporadic colorectal
adenocarcinomas and of colorectal adenocarcinomas arising on a
background of colitis were obtained from the archives of
University Hospital, Birmingham and the Royal Free Hospital,
London respectively. Sections were examined by immunohisto-
chemistry using the streptavidin–biotin indirect immunoperox-
idase method. Antibodies JCMC against Dsc1 (North et al, 1996),
610120 against Dsc2 (Progen, Heidelberg, Germany) and U114
against Dsc3 (Progen) were used. Immunostained material was
assessed by two independent observers and immunoreactivity
compared to that of normal colon.
Western blotting
Sporadic tumour samples with matched specimens of histologi-
cally normal, large bowel mucosa were collected with patient
consent at the time of tumour resection according to local ethical
guidelines. Normal mucosa was obtained from a cancer-free
patient undergoing a total colectomy. Protein lysates were
prepared using TRI Reagent (Molecular Research Center, Cincin-
nati, OH, USA) and Western blots were probed with antibodies (as
above) against Dsc1, Dsc2 and Dsc3. An antibody against keratin 8
(clone C51; Zymed, San Francisco, CA, USA) was used as a loading
control for epithelial protein.
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sRT–PCR
Total RNA was prepared using TRI Reagent and first-strand cDNA
synthesis was performed using a kit (Roche, Lewes, Sussex, UK),
random primers and total RNA (1mg). For semiquantitative RT–
PCR, an aliquot (1ml) of the first-strand cDNA reaction was
amplified with primer pairs 1, 2 and 3 (Supplementary Table 1)
against Dsc1, Dsc2 and Dsc3, respectively. Normalisation was
carried out using primer pair 4 against the housekeeping gene
glyceraldehyde 30 phosphate dehydrogenase. For quantitative
RT—PCR, an aliquot of the first-strand cDNA reaction was
amplified with primer pairs 5, 6 and 7 (Supplementary Table 1). A
Sybr Green PCR master mix (Applied Biosystems, Warrington,
Cheshire, UK) was used and normalisation was carried out using
primer pair 8 against the gene encoding the epithelial protein
keratin 8 (Supplementary Table 1).
Southern blotting
DNA was resolved by agarose gel electrophoresis, transferred onto
Biodyne B membrane (Pall) and probed using a T4 kinase end-
labelled Dsc1-specific oligonucleotide (CCAGTGGTGAAGGCTT
AAGGT).
RESULTS
Reduced expression of Dsc2 in sporadic colorectal
adenocarcinoma
In normal colonic epithelium Dsc2 showed strong staining at the
cell membrane as expected (Figure 1A). A reduction in Dsc2
protein expression was found in eight of 16 sporadic cancer
specimens examined (Figure 1B). There was no relationship
between Dsc2 expression status and any of the clinicopathological
variables analysed (Supplementary Table 2). In tumour samples,
Dsc2 showed both a reduction in expression and a relocalisation
from the membrane to the cell cytoplasm (Figure 1B). To confirm
that Dsc2 expression is lost in colorectal cancer a further 16
samples were analysed by Western blotting. Reduced levels of Dsc2
protein were found in 11 out of 16 (Figure 1C).
De novo expression of Dsc1 and Dsc3
Dsc2 is the only desmocollin produced by simple epithelial tissues
such as the colon (Nuber et al, 1995). To determine whether loss of
Dsc2 was accompanied by de novo expression of Dsc1 and Dsc3,
we examined sporadic colorectal cancers (those previously
analysed for Dsc2 expression by immunohistochemistry) using
antibodies specific for Dscs 1 and 3. As expected, no Dsc1 or Dsc3
expression was detected in normal colon (Figure 2A and B).
Surprisingly, Dsc1 expression was detected in all 16 tumour
samples examined (Figure 2C). In these samples, staining was
found both at the cell membrane and in the cell cytoplasm. Dsc3
exhibited a similar pattern of expression in seven of 16 samples
(Figure 2D). Inappropriate expression of Dsc1 and Dsc3 was
restricted to morphologically abnormal glands. De novo expression
of Dsc1 and Dsc3 was not entirely dependent on loss of Dsc2 as
Dsc1 was expressed in all tumour specimens and Dsc3 was
detected in three of eight samples that showed normal levels of
Dsc2 (Supplementary Table 3). Loss of E-cadherin has been
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Figure 1 Reduced expression of Dsc2 in sporadic colorectal cancer.
Dsc2 is localised at the cell membrane (brown staining) in normal colonic
epithelium (A) but shows reduced immunoreactivity and a relocalisation
from the membrane to the cell cytoplasm in colorectal adenocarcinoma
(B). (C) Loss of expression of Dsc2 by Western blotting. Note that the
antibody used does not detect the smaller Dsc2 ‘b’ protein. N, normal; T,
tumour, K8, keratin 8 loading control for epithelial protein. Bar, 50mm.
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Figure 2 De novo expression of Dsc1 and Dsc3 in sporadic colorectal
cancer. Dsc1 (A) and Dsc3 (B) are not expressed in normal colonic
epithelial tissue, but exhibit de novo expression in colonic adenocarcinoma
(Dsc1, C; Dsc3, D). In (C) and (D) staining is present both at the
membrane and in the cell cytoplasm. (E) Dsc1 and Dsc3 are not present in
normal colonic epithelium (lane 8), but bands of the expected size
(corresponding to the Dsc ‘a’ and ‘b’ proteins) were detected by Western
blotting in a subset of tumour samples. Samples in lanes 3–5 were
adjudged to be positive for Dsc1 (a and b proteins) and Dsc3 (a and b),
while that in lane 7 was adjudged positive for Dsc1 (a and b) alone. Bands
corresponding in size to Dsc1b and Dsc3b were also detected in the
samples in lanes 1 and 7 respectively. The band in lane 6 (lower panel) is
nonspecific. Samples in lanes 1 and 3 showed no change in Dsc2, while
those in lanes 4–7 showed a reduction in Dsc2 expression (not shown).
The sample in lane 2 was not tested for Dsc2. N, normal; T, tumour. Bar,
50mm.
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expression of E-cadherin in nine of 16 sporadic tumours. Dsc2
expression was lost in seven of nine of these, with the remaining
two showing normal Dsc2 expression (Supplementary Table 3).
To confirm the presence of Dsc1 and Dsc3 in colorectal cancer,
seven new samples of adenocarcinoma were compared with
normal colonic epithelial tissue by western blotting. Bands of the
expected molecular weight were detected in four of seven (Dsc1)
and three of seven (Dsc3)(Figure 2E). No evidence was found for
the presence of either DC in normal tissue (Figure 2E).
RNA expression profile
Semiquantitative RT–PCR was used to determine whether loss of
Dsc2 protein was accompanied by loss of RNA. Four pairs of
matched samples, not previously examined, were used. Transcrip-
tion of Dsc2 was not altered in any of the four tumours
(Figure 3A). However, both Dsc1 (3/4) and Dsc3 (3/4) mRNA
was clearly upregulated. To quantify changes in desmocollin
expression, we examined a further seven samples by quantitative
RT–PCR (Figure 3B). Similar results were found to those obtained
using semiquantitative RT–PCR. Thus, although an increase in
Dsc2 message levels was found in one sample, the majority (six of
seven) showed no significant changes in Dsc2 transcription (i.e.
there was o2-fold difference in expression levels between tumour
samples and matched controls) (Figure 3B). In no case was
transcription of Dsc2 downregulated. As before, increases in Dsc1
and Dsc3 mRNA (42-fold) were detected in a significant number
of cases (three of seven and four of seven tumours respectively)
(Figure 3B).
A summary of the results from immunohistochemistry, Western
blotting and RT–PCR is given in Supplementary Table 4.
Desmocollin switching occurs in colorectal
adenocarcinoma on a background of colitis
To determine whether desmocollin switching was exclusive to
sporadic tumours, we examined expression of Dscs 1–3 in a series
of colitis-associated colorectal adenocarcinomas. Analysis was
restricted to immunohistochemistry as samples were available only
as paraffin-embedded sections. The median age of patients with
colitic tumours was less than those with sporadic tumours, but
tumour stage, differentiation grade, site and microsatellite in-
stability were comparable between groups (Supplementary Table
2). In tumours on a background of colitis, loss of Dsc2 was
observed in eight of 19 specimens examined, and de novo
expression of Dsc1 and Dsc3 was detected in 11 of 19 and six of
19 specimens respectively (Supplementary Table 4). E-cadherin
expression was lost in 16 of 19 colitic tumours. Thus, in common
with previous studies (Aust et al, 2001), we found that E-cadherin
more commonly showed decreased expression in colitic rather than
sporadic tumours (84 vs 56%). Dsc2 expression was lost in all 16
colitic tumours that showed loss of E-cadherin (data not shown).
DISCUSSION
In this report, we show for the first time that Dsc2 protein
expression is reduced in colorectal cancer, and that this is
accompanied by de novo expression of Dsc1 and Dsc3. These
changes in Dsc expression pattern may result in significant
alterations in desmosome function, but do not result in the
complete loss of desmosomes from colorectal cancer tissue
(Collins et al, 1990). However, it is possible that the size and
number of desmosomes is reduced (Bosch et al, 2005). To date,
only switching between classical cadherin molecules has been
described (e.g. Tomita et al, 2000; Hardy et al, 2002). The
functional significance of switching between desmosomal cadher-
ins remains unknown, but will be an important area of future
investigation.
In no case was loss of Dsc2 message detected, suggesting that
transcriptional mechanisms are not responsible for the loss of
Dsc2 protein. The most plausible explanation for the reduction in
Dsc2 protein is loss of stability. One possibility is that this could be
caused by a loss of cell–cell contact, perhaps as a result of loss of
expression of E-cadherin, as desmocollins are rapidly degraded in
the absence of intercellular contacts (Penn et al, 1987). However, it
should be noted that in some cases it appears that Dsc2 expression
is lost in the presence of normal amounts of E-cadherin
(Supplementary Table 3). No reduction in desmocollin expression
was found in the only previous study of desmosomes in colorectal
cancer (Collins et al, 1990). The most likely explanation for the
discrepancy lies in the antibodies used. We have been careful to
use antibodies specific for individual Dsc isoforms. Collins et al
(1990) carried out their study before all of the desmocollin
isoforms had been discovered and their antibody may have reacted
with more than one isoform.
Increased amounts of message encoding both Dsc1 and Dsc3
were detected in cancer specimens. The mechanism by which this
occurs is not clear. All seven DC genes are clustered in the same
region of chromosome 18q (Hunt et al, 1999), and their expression
may be linked (North et al, 1996; King et al, 1997). Induction of
Dsc1 and Dsc3 RNA could be a compensatory response to the loss
of Dsc2 protein. In a similar way, loss of Dsc1 protein from the
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Figure 3 RNA encoding Dsc2 is unchanged, whereas that encoding
Dsc1 and Dsc3 is increased in sporadic adenocarcinoma. (A) Semiquanti-
tative RT–PCR was used to measure RNA in matched specimens of
histologically normal tissue and tumour material. In each case, PCR
products were of the expected size and identical in mobility to those
amplified from reverse transcribed RNA from normal human epidermal
keratinocytes (not shown). To confirm the presence of Dsc1 message in
colorectal cancer samples, amplified DNA was blotted onto nitrocellulose
and probed with a Dsc1-specific oligonucleotide (predicted to hybridise
within the PCR fragment). (B) Levels of RNA encoding Dsc1, Dsc2 and
Dsc3 were compared for a further seven matched pairs by quantitative
RT–PCR.
Desmocollin switching in colorectal cancer
K Khan et al
1369
British Journal of Cancer (2006) 95(10), 1367–1370 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sepidermis of knockout mice results in large (420-fold) increases
in Dsc2 RNA (M Chidgey, unpublished). The mechanism whereby
an increase in Dsc1 and Dsc3 message levels could result from a
loss of Dsc2 protein (while Dsc2 mRNA remains unchanged)
remains to be determined.
The changes in desmocollin expression profile were similar in
both sporadic and colitis-associated colorectal cancer. These
changes could significantly reduce the adhesion between colonic
epithelial cells resulting in an increased propensity of the cells to
proliferate, invade surrounding tissues and undergo metastasis.
Switching of desmocollin isoforms could also affect the localisation
of cytoplasmic desmosomal constituents, and indeed a redistribu-
tion of g-catenin (plakoglobin) from the membrane to the
cytoplasm does occur in both sporadic adenocarcinoma (Kolligs
et al, 2000) and adenocarcinoma arising on a background of colitis
(our unpublished data). The effects of this redistribution are
unknown, but one downstream consequence of g-catenin signal-
ling is strong activation of the oncogene c-myc (Kolligs et al, 2000).
It is also possible that disturbances in desmocollin expression
profile could affect b-catenin signalling. Increased b-catenin
transcriptional activity has been detected in both Dsc1 null mice
(Merritt et al, submitted), and in transgenic mice that exhibit
disturbances in the normal balance between desmocollin isoforms
in the epidermis (Hardman et al, 2005). Increased b-catenin
signalling (as a result of APC mutation) is a common causative
event in colorectal cancer, and it is conceivable that DC switching
could contribute to b-catenin dysregulation and so play a
contributory role in the initiation of the early stages of colorectal
tumorigenesis.
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